Loading
collectionsCollection
ADCdb / ADC Review
ADCdb and ADC Review are where to track the hundreds of ADCs in trials, with target, payload, and linker.
Overview
ADCdb and ADC Review together provide curated coverage and databases of antibody-drug conjugates in development, letting a reader track the hundreds of ADCs in trials by target, payload and linker. ADCdb is an academic database from Zhejiang University that structures more than 6,000 ADC records, while ADC Review, published by Sunvalley Communication, covers conference data from AACR, ASCO and ESMO. The licence is mixed across the two resources. On OnCo the collection is linked to the technology Antibody-drug conjugate (ADC) and to the separate ADC Review source record, and it is cited by the bottleneck Biomarkers are not validated or standardised.
Holds
Curated coverage and databases of antibody-drug conjugates in development.
Licence
Mixed
Maintainer
ADC Review (Sunvalley Communication); academic ADCdb (Zhejiang University)
Similar pages
- IdeaUse SLFN11 status to decide which antibody-drug payload to give next
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- IdeaCheck whether a tumour can still show itself to the immune system
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- IdeaReflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- TrialDESTINY-Breast06
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperPOLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperTROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- IdeactDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- TechnologyTROP2 PET
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).